Search





Search





Markets
/
Stocks
/
nasdaq-alt
/

Altimmune Inc

ALT

Add to Watchlist

2.915USD

-0.105-3.48%

Close 05/14, 16:00（ET）Quotes delayed by 15 min

278.67MMarket Cap

LossP/E TTM



Altimmune Inc

2.915

-0.105-3.48%

Overview Financials Discussions Analysis Company

TradingKey Stock Score

Overall Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Peer Comparison

Overview

Financials

Discussions

Analysis

Company

TradingKey Stock Score

Overall Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Peer Comparison

TradingKey Stock Score of Altimmune Inc

Currency: USD Updated: 2026-05-13

Key Insights

Altimmune Inc's fundamentals are relatively healthy, with an industry-leading ESG disclosure.and its growth potential is high.Its valuation is considered fairly valued, ranking 117 out of 383 in the Biotechnology & Medical Research industry.Institutional ownership is very high.Over the past month, multiple analysts have rated it as Buy, with the highest price target at 19.35.In the medium term, the stock price is expected to trend down.Despite a weak stock market performance over the past month, the company shows strong fundamentals and technicals.The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.

Altimmune Inc's Score

Industry at a Glance

Industry Ranking

117 / 383

Overall Ranking

234 / 4487

Industry

Biotechnology & Medical Research

Support & Resistance

Relevant data have not been disclosed by the company yet.

Score Analysis

Current score

Previous score

Media Coverage

Last 24 hours

Coverage Level

Very Low

Very High

Negative

Altimmune Inc Highlights

StrengthsRisks

Altimmune, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on developing next-generation peptide-based therapeutics. It is developing pemvidutide, a GLP-1/glucagon dual receptor agonist for the treatment of obesity, metabolic dysfunction-associated steatohepatitis (MASH) and other indications. Activation of the GLP-1 and glucagon receptors is believed to mimic the complementary effects of diet and exercise on weight loss, with GLP-1 suppressing appetite and glucagon increasing energy expenditure. Glucagon is also recognized as having direct effects on hepatic fat metabolism, to rapid reductions in levels of liver fat and serum lipids. The Company has completed the MOMENTUM Phase II obesity trial and is being studied in the IMPACT Phase IIb MASH trial. The Company also develops and commercializes surfactant-functionalized (EuPort domain) incretin-based peptide therapeutics, including (GLP-1-glucagon)/oxyntomodulin, and variants.

Growing

The company is in a growing phase, with the latest annual income totaling USD 41.00K.

Overvalued

The company’s latest PE is -3.28, at a high 3-year percentile range.

Institutional Buying

The latest institutional holdings are 57.72M shares, increasing 7.43% quarter-over-quarter.

Held by PRFDX

Star Investor PRFDX holds 8.68K shares of this stock.

Higher Market Activity

The company has more investor interest, with a 20-day turnover ratio of 0.39.

Analyst Rating

Based on 11 analysts

Buy

Current Rating

19.350

Target Price

+526.21%

Upside Space

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

Financial Health

Currency: USD Updated: 2026-05-13

The current financial score of Altimmune Inc is 7.00, ranking 142 out of 383 in the Biotechnology & Medical Research industry. Its financial status is stable, and its operating efficiency is low. Its latest quarterly revenue reached 0.00, representing a year-over-year decrease of 100.00%, while its net profit experienced a year-over-year decrease of 15.26%.

Score

Industry at a Glance

Previous score

7.00

Change



Financials

7.26

Key Metrics

Cash and cash equivalents

Total assets

Total liabilities

Free cash flow

Relevant data have not been disclosed by the company yet.



Quality of Earnings

7.71

Key Metrics

Total revenue

Operating profit

Total assets

SG&A

Relevant data have not been disclosed by the company yet.



Operational Efficiency

2.94

Key Metrics

Cash flow from operating activities

Income after tax

Relevant data have not been disclosed by the company yet.



Growth Potential

9.65

Key Metrics

Cash flow from operating activities

Total revenue

Relevant data have not been disclosed by the company yet.



Shareholder Returns

7.46

Key Metrics

Free cash flow

Relevant data have not been disclosed by the company yet.

Altimmune Inc's Company Valuation

Currency: USD Updated: 2026-05-13

The current valuation score of Altimmune Inc is 6.30, ranking 290 out of 383 in the Biotechnology & Medical Research industry. Its current P/E ratio is -3.28, which is -57.41% below the recent high of -1.40 and -184.64% above the recent low of -9.32.

Score

Industry at a Glance

Previous score

6.30

Change

Valuation Dimensions

P/E

P/B

P/S

P/CF

Industry Ranking 117/383

Relevant data have not been disclosed by the company yet.

Earnings Forecast

Currency: USD Updated: 2026-05-13

The current earnings forecast score of Altimmune Inc is 7.82, ranking 273 out of 383 in the Biotechnology & Medical Research industry. The average price target is 20.00, with a high of 28.00 and a low of 1.00.

Score

Industry at a Glance

Previous score

7.82

Change

Support & Resistance

Relevant data have not been disclosed by the company yet.

Analyst Rating

Based on 10 analysts

Buy

Current Rating

19.350

Target Price

+526.21%

Upside Space

Strong Buy

Buy

Hold

Sell

Strong Sell

Peer Comparison

554

Total

Median

Average

Company name

Ratings

Analysts

Altimmune Inc

ALT

CRISPR Therapeutics AG

CRSP

IQVIA Holdings Inc

IQV

Beigene Ltd

ONC

argenx SE

ARGX

Ionis Pharmaceuticals Inc

IONS

...

111

Financial Forecasting

EPS

Revenue

Net Profit

EBIT

Relevant data have not been disclosed by the company yet.

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

Price Momentum

Currency: USD Updated: 2026-05-13

The current price momentum score of Altimmune Inc is 7.26, ranking 119 out of 383 in the Biotechnology & Medical Research industry. Currently, the stock price is trading between the resistance level at 3.59 and the support level at 2.51, making it suitable for range-bound swing trading.

Score

Industry at a Glance

Previous score

7.33

Change

-0.07

Support & Resistance

Relevant data have not been disclosed by the company yet.

Indicators



The Indicators feature provides value and direction analysis for various instruments under a selection of technical indicators, together with a technical summary.

This feature includes nine of the commonly used technical indicators: MACD, RSI, KDJ, StochRSI, ATR, CCI, WR, TRIX and MA. You may also adjust the timeframe depending on your needs.

Please note that technical analysis is only part of investment reference, and there is no absolute standard for using numerical values to assess direction. The results are for reference only, and we are not responsible for the accuracy of the indicator calculations and summaries.

Indicators

Sell(1)

Neutral(4)

Buy(1)

Indicators

Value

Direction

MACD(12,26,9)

0.073

Neutral

RSI(14)

45.664

Neutral

STOCH(KDJ)(9,3,3)

70.225

Neutral

ATR(14)

0.170

Low Volatility

CCI(14)

21.949

Neutral

Williams %R

34.286

Buy

TRIX(12,20)

-0.437

Sell

StochRSI(14)

0.000

Oversold

Moving Average

Sell(6)

Neutral(0)

Buy(0)

Indicators

Value

Direction

MA5

3.064

Sell

MA10

3.008

Sell

MA20

3.072

Sell

MA50

3.280

Sell

MA100

3.893

Sell

MA200

3.990

Sell

Institutional Confidence

Currency: USD Updated: 2026-05-13

The current institutional shareholding score of Altimmune Inc is 3.00, ranking 193 out of 383 in the Biotechnology & Medical Research industry. The latest institutional shareholding proportion is 30.53%, representing a quarter-over-quarter decrease of 32.53%. The largest institutional shareholder is Invesco, holding a total of 171.18K shares, representing 0.09% of shares outstanding, with 74.80% increase in holdings.

Score

Industry at a Glance

Previous score

3.00

Change

Institutional Shareholding

Relevant data have not been disclosed by the company yet.

Shareholder Activity

Name

Shares Held

Chg %

BlackRock Institutional Trust Company, N.A.

7.85M

+35.43%

State Street Investment Management (US)

5.12M

+42.16%

Nuveen LLC

1.24M

+516.93%

Geode Capital Management, L.L.C.

2.29M

+13.63%

Risk Assessment

Currency: USD Updated: 2026-05-13

The U.S. Dollar Index is currently in a neutral state, which has a neutral effect on the Biotechnology & Medical Research domestic-focused industry. The Dollar Index (DXY) measures the value of the U.S. dollar against a basket of major currencies, including the euro, yen, pound sterling, Canadian dollar, Swedish krona, and Swiss franc. The current risk assessment score of Altimmune Inc is 4.26, ranking 89 out of 383 in the Biotechnology & Medical Research industry. The company's beta value is 0.19. This indicates that the stock tends to underperform the index during upward trending markets but experiences smaller declines during downward trending markets. Altimmune Inc’s latest ESG disclosure leads the Biotechnology & Medical Research industry, indicating outstanding, compliant performance across environmental management, social responsibility, and governance, which may help mitigate overall risk.